Phio Pharmaceuticals CORP Form 4 insider transactions

Robert J. Bitterman, Director and CEO of Phio Pharmaceuticals Corp., acquired 10,000 shares of common stock on June 26, 2026.

Phio Pharmaceuticals Director Curtis Lockshin was granted 16,600 restricted stock units, vesting on the first anniversary of the grant.

Phio Pharmaceuticals Director Jonathan Freeman acquired 16,600 shares of common stock in the form of restricted stock units, increasing his beneficial ownership to 32,655 shares.

Phio Pharmaceuticals Corp. Director David H. Deming was granted 23,800 restricted stock units, vesting in one year.

Phio Pharmaceuticals Corp.'s Chief Financial Officer, Lisa Cabott Carson, was granted 47,000 restricted stock units, vesting on the first anniversary of the grant date.

Phio Pharmaceuticals Corp. Director Patricia A. Bradford acquired 18,500 shares of common stock through the vesting of restricted stock units.

Phio Pharmaceuticals Corp. CEO Robert J. Bitterman was granted 120,000 restricted stock units, vesting on the first anniversary of the grant date.

Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, acquired 5,000 shares of common stock.

Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, purchased 5,000 shares of common stock.

Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, purchased 5,000 shares of common stock at $1.14 per share.

Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, purchased 5,000 shares of common stock at $1.27 per share.

Phio Pharmaceuticals Corp. Director Robert L. Ferrara filed an amended Form 4 correcting the number of restricted stock units granted.

Phio Pharmaceuticals director David H. Deming was granted 14,000 restricted stock units, vesting in one year, as disclosed in a recent SEC Form 4 filing.

Phio Pharmaceuticals director Curtis Lockshin was granted 16,200 restricted stock units, vesting in one year, as reported in a recent SEC filing.

Phio Pharmaceuticals Corp. Director Jonathan E. Freeman was granted 14,700 restricted stock units, vesting in one year, increasing his beneficial ownership to 16,055 shares.

Phio Pharmaceuticals Director Robert L. Ferrara acquired 23,000 restricted stock units, increasing his beneficial ownership to 38,666 shares.

Phio Pharmaceuticals Corp. granted its VP of Finance and Administration, Lisa Cabott Carson, 47,000 restricted stock units vesting in one year.

Phio Pharmaceuticals Corp. Director Patricia A. Bradford reported the acquisition of 18,800 restricted stock units, increasing her beneficial ownership to 27,151 shares.

Phio Pharmaceuticals CEO Robert J. Bitterman reported recent stock transactions, including the acquisition of 250,000 restricted stock units and the disposition of 4,111 shares for tax withholding, while also granting a power of attorney for SEC filings.

Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, has increased his direct ownership in the company by purchasing 2,000 shares of common stock.

Phio Pharmaceuticals Corp. Director Robert L. Ferrara has acquired 2,500 shares of common stock at $2.4199 per share, increasing his total beneficial ownership to 15,666 shares.

Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, acquired 1,500 shares of common stock at $2.75 per share, increasing his beneficial ownership to 25,149 shares.

Robert Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp., recently purchased additional shares of the company's common stock.

Robert L. Ferrara, a director of Phio Pharmaceuticals Corp., purchased 2,500 shares of common stock at a weighted average price of $1.82 on May 20, 2025.

Robert M. Infarinato, VP and CFO of Phio Pharmaceuticals Corp., reports acquiring 3,000 shares of common stock and disposing of 11,000 shares.

Director Jonathan E. Freeman acquired 1,000 shares of Phio Pharmaceuticals Corp. through the vesting of a restricted stock unit on September 11, 2024.

Robert J. Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp., acquired 15,500 shares of common stock through the vesting of a restricted stock unit on September 11, 2024.

Director Curtis Lockshin acquired 2,000 shares of Phio Pharmaceuticals Corp. common stock on September 11, 2024, through a restricted stock unit grant.

Robert L. Ferrara, a director of Phio Pharmaceuticals Corp., acquired 10,000 shares of common stock on September 11, 2024, through a restricted stock unit grant.

Patricia A. Bradford, a director of Phio Pharmaceuticals Corp., acquired 8,000 shares of common stock on September 11, 2024, through a restricted stock unit grant.